Veterinary scientists have given the first ever clinical proof of the effect of joint supplements on dogs' mobility, following a rigorous two-and-a-half year research study into YUMOVE.

State-of-the-art activity monitors, which were originally developed to track wild cat movements on the African plains, were used by specialists at the Royal Veterinary College (RVC) to record dogs' mobility levels in their home environment for 42 days. In the placebo-controlled study the dogs on YUMOVE were significantly more mobile after just 6 weeks of use.

It's the first time a joint supplement has been clinically proven and in such a short period, meaning YUMOVE can be recommended to dog owners with confidence.

The clinical study was sponsored by YUMOVE manufacturer Lintbells Ltd, who announced the results at the prestigious veterinary event BSAVA Congress this month.

Co-founder Dr John Howie said: "This is a really exciting development for us, because although we had significant feedback from dog owners and vets about how well YUMOVE worked, we felt it was important to establish independent, rigorous clinical evidence.

"There is a great deal of uncertainty and confusion when it comes to joint supplements but this study will give clarity to those advising dog owners."

Lead investigator at the RVC Dr Matthew Pead declared the study a major step forward for canine mobility.

"It took nine months of careful planning to ensure a robust methodology was developed to provide clear clinical results that can be relied on with confidence," said Dr Pead.

Dr Howie concluded: "With an estimated 1.2 million dogs suffering from joint and mobility issues and only approximately 10 to 15 per cent receiving a nutritional supplement, Lintbells believes that providing an affordable, proven product that owners can rely on will uncap the significant market opportunity for specialist pet suppliers."

For more information please visit www.lintbells.com

Pictured: Dr Matthew Pead (left) and Dr John Howie at BSAVA Congress.